Deepthi Kolli, Ph.D.

Deepthi Kolli, Ph.D has over 15 years of cell therapy and biologics development and commercialization experience. Dr. Kolli has worked at and/or advised numerous cell and gene therapy companies on a vast array of CMC topics including development, technology transfer, CDMO selection, validation, comparability, regulatory submissions and interactions, and CMC strategy.

Previously, Dr. Kolli served as Vice President of Process Sciences at ImmPACT Bio, where she led a team of scientists and engineers responsible for process development, analytical development, technology transfer, manufacturing support, quality control and overall CMC activities for bispecific CAR T cell therapeutics. Prior to joining ImmPACT Bio, she held increasing leadership roles at Sonoma Bio, Atara Bio and Charles River focusing on both autologous and allogeneic cell therapy products. She has hands on experience on various cell therapy products (CAR T, CAR Treg, CIK, CAR NK, iPSCs, HSC derived hybrid cells, Allogeneic T cells to name a few) in terms of starting cell material characterization, clinical correlations, specification setting, EOS, potency assay development, lyophilization, Quality investigations, NC/CAPA’s, and risk analysis and has presided over transfer, validation and submissions of numerous products.  Dr. Kolli has extensive regulatory submissions and interactions including in the US, EU, China and Japan.

Deepthi holds a Ph.D and M.S in Immunology from the National Dairy Research Institute, and a B.Sc in Biochemistry and Microbiology from Nagarjuna University in India.